"We Envision Growth Strategies Most Suited
to Your Business"
The global immunology market size is expected to gain momentum by reaching USD 158.69 billion by 2028. This information is published by Fortune Business Insights in its report, titled “Immunology Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb), and Others); By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Regional Forecast, 2021-2028.” The report further mentions that the market stood at USD 85.74 billion in 2020 and is likely to exhibit a CAGR of 8.1% between 2021 and 2028.
The U.S. FDA Approves STELARA by Janssen to Treat Pediatric Psoriasis
In July 2020, Janssen Pharmaceuticals, a part of Johnson & Johnson, announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for its effective drug, STELARA. The company reports that the drug is effective in treating pediatric psoriasis and its administration brings relief for patients suffering from skin plaques or lesions. The drug targets both the interleukin IL-23 and IL-12 that is responsible for modulating the overactive inflammatory response in several autoimmune disorders. STELARA can be administered through injection four times a year after the initial two starter doses. The approval is expected to positively impact the sales revenue of the company that is highly focused on delivering meaningful immunology solutions for the patients.
To get a detailed report summary and research scope of this market, click here:
Increasing Prevalence of Autoimmune Diseases to Propel Market Growth
According to a research article by the National Stem Cell Foundation, around 4% of the global population suffers from at least one of 80 different autoimmune diseases annually. The increasing prevalence of autoimmune diseases due to several factors such as stress, gut dysbiosis, dietary components, and others is driving the attention of the manufacturers to develop advanced drug solutions to combat the disorders. For instance, in September 2020, Lupin announced the launch of a generic rheumatoid arthritis drug, Leflunomide, in the U.S. Therefore, these factors are expected to contribute to the global market growth in the forthcoming years.
Collaboration between Prominent Companies to Expand Their Product Portfolio and Boost Sales Revenue
The market comprises small, medium, and large companies striving to maintain a stronghold by collaborating with other companies to develop advanced immunology drug solutions to cater to the rising healthcare industry’s demand. Besides, other key players are further adopting organic and inorganic growth strategies such as merger and acquisition, partnership, and facility expansion to maintain their footprint in the fiercely competitive global marketplace.
List of the Companies Profiled in the Global Market:
Further Report Findings:
Table of Segmentation:
Value (USD billion)
By Drug Class
By Disease Indication
By Distribution Channel